Replies to post #175659 on Biotech Values

[mcbio]

I agree with ‘genisi’ that GlobeImmune’s HCV program is obsolete. (A 2010 PR on the program is in #msg-49095438.)

Certainly agree that the HCV program seems obsolete but, if this comes public at sub-$100M market cap and there is any hope at all for any of their other programs partnered with GILD (HBV) or CELG (oncology), might be an interesting risk-reward.